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Direct Arterial Injection of Hyperpolarized 13C-Labeled
Substrates into Rat Tumors for Rapid MR Detection of
Metabolism with Minimal Substrate Dilution
Steven Reynolds,1* Stephen Metcalf,2z Edward J. Cochrane,3 Rebecca C. Collins,3
Simon Jones,3 Martyn N.J. Paley,1 and Gillian M. Tozer2
Purpose: A rat model was developed to enable direct admin-
istration of hyperpolarized 13C-labeled molecules into a tumor-
supplying artery for magnetic resonance spectroscopy (MRS)
studies of tumor metabolism.
Methods: Rat P22 sarcomas were implanted into the right ingui-
nal fat pad of BDIX rats such that the developing tumors received
their principle blood supply directly from the right superior epi-
gastric artery. Hyperpolarized 13C-molecules were either infused
directly to the tumor through the epigastric artery or systemically
through the contralateral femoral vein. Spectroscopic data were
obtained on a 7 Tesla preclinical scanner.
Results: Intra-arterial infusion of hyperpolarized 13C-pyruvate
increased the pyruvate tumor signal by a factor of 4.6, com-
pared with intravenous infusion, despite an approximately 7
times smaller total dose to the rat. Hyperpolarized glucose sig-
nal was detected at near-physiological systemic blood con-
centration. Pyruvate to lactate but not glucose to lactate
metabolism was detected in the tumor. Hyperpolarized 13C-
labeled combretastatin A1 diphosphate, a tumor vascular dis-
rupting agent, showed an in vivo signal in the tumor.
Conclusions: The model maximizes tumor substrate/drug
delivery and minimizes T1 relaxation signal losses in addition
to systemic toxicity. Therefore, it permits metabolic studies of
hyperpolarized substrates with relatively short T1 and opens
up the possibility for preclinical studies of hyperpolarized drug
molecules. Magn Reson Med 000:000–000, 2017. VC 2017
The Authors Magnetic Resonance in Medicine published
by Wiley Periodicals, Inc. on behalf of International Society
for Magnetic Resonance in Medicine. This is an open
access article under the terms of the Creative Commons
Attribution License, which permits use, distribution and
reproduction in any medium, provided the original work is
properly cited.
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INTRODUCTION
Hyperpolarized dissolution dynamic nuclear polarization
(dDNP) is an established technology for in vivo monitor-
ing of metabolism by magnetic resonance spectroscopy
(MRS) and MRI, without the interfering background sig-
nals experienced in 1H MRS (1,2). After dissolution, the
hyperpolarized substrate is rapidly administered to
experimental animals, and signals are acquired from
metabolites within a few multiples of the T1 relaxation
time, before the signal decay becomes too significant.
The most commonly used hyperpolarized substrate, 13C1-
pyruvate, has a reported T1 of approximately 50 s for in
vitro aqueous solutions, whereas in vivo values, includ-
ing those for extracted blood, have been estimated in the
range of 17 to 30 s (3–5). The search for other metabolic
targets for hyperpolarization has focused on molecular
groups with inherently long T1, such as those with car-
bonyl groups and deuterated compounds. Unfortunately,
many metabolically active molecules and drug candi-
dates have short T1s of 1 to 20 s, which are difficult to
apply in preclinical discovery research because of the
strong correlation between the observed T1 and signal
enhancement (6). An alternative is the development of
molecular probes in which the spin system is capable of
being put into a singlet state (7), which considerably
lengthens the magnetization relaxation time. However,
this approach has so far established very few suitable
probes.
Typically, hyperpolarized substrates are administered
systemically to mice or rats through an intravenous
injection. However, a potential pitfall with dDNP hyper-
polarization is the supra-physiological quantities of sub-
strate required to acquire an acceptable signal-to-noise
ratio (SNR) in the tissue of interest. For the most com-
mon hyperpolarized molecules, the dose is well-
tolerated (eg, pyruvate and urea), or their injected con-
centration is close to the endogenous blood concentra-
tion (eg, lactate (8) and glucose (9)). No adverse reactions
have been reported for these substrates. However, use of
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such high concentrations of substrates/metabolites per-
turbs tissue biochemistry and, if hyperpolarized drug
candidates are to be used, then the required concentra-
tion for successful MR signal acquisition is likely to be
well above their maximum tolerated doses.
This problem would be substantially reduced if the
hyperpolarized substrate could be administered directly
to the tissue of interest, thus avoiding substrate dilution
and minimizing the time required to reach the tissue.
Indeed, this has been done in ex vivo perfusions of rat
hearts for metabolism studies (10,11). For cancer studies,
specialized tumor models have been developed in which
most of the tumor blood supply arises from a single sup-
plying artery and draining vein (12,13). Such “tissue-
isolated” models have been used recently for studying
the circadian effects on tumor metabolism (14) and
tumor response to vascular targeting agents (15). Howev-
er, no work has been reported on their use in MRS/MRI
studies of tumor metabolism using hyperpolarized sub-
strates. Here, we report the signal enhancement achiev-
able for 13C1-pyruvate and
13Cu-glucose-d7 using direct
injection into a tumor-supplying artery. Additionally, in
vivo monitoring of drug metabolism was evaluated for
the first time by administering a custom synthesized
hyperpolarized 13C-labeled version of the vascular dis-
rupting pro-drug, combretastatin A-1-diphosphate (CA1-
P) (16).
METHODS
Animal Preparation
Animal experiments were conducted in accordance with
the UK Animals Act 1986, with local ethical approval
and following published ethical guidelines (17). The sur-
gical procedure for growing tissue-isolated tumors in the
rat inguinal fat-pad was slightly modified from our previ-
ously described method (12). Briefly, 9 to 13-week-old
in-bred immuno-competent BDIX rats from an in-house
specific pathogen free colony (mostly male; see fig.
legends for details) were anesthetized using isoflurane
(5% induction; 2% maintenance; balance O2). The right
inguinal fat pad was exposed and a portion bluntly dis-
sected from the skin to allow its surgical isolation togeth-
er with the proximal portion of the superior epigastric
artery and vein. A total of 1  106 dissociated early pas-
sage syngeneic P22 fibrosarcoma cells (18) in 50 mL
Hanks balanced salt solution, obtained from a donor ani-
mal, were injected into the isolated portion of the fat
pad using a 25-gauge needle. The needle track was tem-
porarily clamped shut to seal the fat and prevent escape
of the cells. The isolated fat pad containing the tumor
cells was loosely sutured to the bulk of the remaining fat
pad to allow movement of the growing tumor, while pre-
venting twisting of the pedicle containing the superior
epigastric artery and vein. The incision was closed with
three horizontal mattress sutures (5/0 vicryl). Two-
percent lidocaine HCl (Hamelin Pharmaceuticals,
Gloucester, UK) was used for immediate topical pain
relief, and buprenorphine (Vetergesic, Alstoe Veterinary,
York, UK; 0.03mg/kg/day for 2 days postoperatively) for
extended analgesia. Rats were kept on a 12 h light/dark
cycle, with temperature maintained at 19 to 23C. They
were housed singly after surgery and provided with
moistened and normal rat chow and water ad libitum.
The developing tumor receives its principle blood sup-
ply directly from the right superior epigastric artery
branching from the right femoral artery, with the superi-
or epigastric vein draining the tumor (Fig. 1). Tumors
were allowed to grow for approximately 7 days before
MR scanning or optical imaging. For preparatory surgery
prior to imaging, anesthesia was maintained using 1 to
2% isoflurane delivered at 2 L/min in 1:1 oxygen:nitrous
oxide. For MR scanning and optical imaging, the same
concentration of isofluorane was used in 22 to 24% O2;
FIG. 1. Representation of the tumor
implant, approximating its location in the
inguinal cleft of a BDIX rat and showing
the vascular morphology and arrange-
ments of the arterial cannula, waste line,
surface coil, phantom, blood pressure
monitor, and diaphragm valve (not to
scale). The arterial cannula is positioned
with its tip just distal to the branch of the
superior epigastric artery from the femoral
artery. The distal portion of the femoral
artery and side branches are ligated such
that infusate from the arterial cannula is
washed into the tumor-supplying superior
epigastric artery via normal arterial blood
flow. The waste line passes above the
13C1-acetate phantom and surface coil,
with a branch for blood pressure monitor-
ing. Direction of flow of the hyperpolarized
solution is controlled via the pinch and
diaphragm valves. Inset shows the
approximate position of the tumor, cannu-
la, waste line, and surface coil with
respect to the whole rat.
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balance N2. Surgery involved right saphenous artery can-
nulation up to the superior epigastric artery branch of
the right femoral artery for substrate delivery (Figs. 1 and
3). Throughout surgery and subsequent procedures, the
animal’s temperature was maintained at 37C using a
homeothermic blanket system (Harvard apparatus, Cam-
bridge, UK), with supplementary heated air for MR scan-
ning. Respiration rate was measured using a surface
transducer (SA Instruments Inc, Stony Brook, NY, USA),
and mean arterial blood pressure was measured with a
pressure transducer (CWE Inc, Ardmore, PA, USA) in
line with the arterial cannula (Fig. 1), to enable monitor-
ing of animal welfare while in the magnet. To prevent
the wound from drying out during scanning, a saline
drip line was directed onto the wound site. The saline
was heated by placing the drip line under the heating
blanket just before entering the wound site, and was sup-
plied at 1mL/h using a syringe pump. The wound was
covered with sterile gauze and protected with Parafilm.
Animals were sacrificed after scanning.
Optical Imaging
Macroscopic and microscopic optical imaging was used
for preliminary studies to visualize the arterial delivery
of compounds to tumor tissue. Following tumor growth
and the surgical procedure described previously, either
5mg/mL methylene blue (methylthioninium chloride;
Proveblue, Marseille, France) or 0.24 mL undiluted fluo-
rescent 15 mm diameter polystyrene microbeads (Fluo-
spheres; excitation 450nm; emission 480nm; Fisher
Scientific, Loughborough, UK) were infused via the
saphenous artery cannula, at 1 L/min using an infusion
pump. For methylene blue infusion, the preparation was
viewed under a Nikon SMZ 1000 (Melville, NY, USA)
operating microscope and the infusion recorded at 13
frames/s for approximately 15 s following the start of
infusion (Jenoptik ProgRes XTcore5 digital camera, Indi-
go Scientific, Baldock, UK). For fluorescent microbeads,
tumors were excised immediately after infusion,
embedded in optimum cutting temperature compound
and snap-frozen, using isopentane cooled on dry ice, and
stored at 80C. Ten-micrometer-thick cryo-sections
were stained by immuno-fluorescence for a rat endotheli-
al cell surface antigen (RECA-1; Serotec, Kidlington, UK)
with Alexa Fluor 555 tagged anti-mouse secondary
(ThermoFisher Scientific, Loughborough, UK). Cell
nuclei were stained using DAPI in the mounting medium
(Vector Laboratories, Peterborough, UK). Tumor sections
were imaged using either an Olympus BX61 (Tokyo, Japan)
fluorescence microscope for single fields or a Leica
AF6000 (Wetzlar, Germany) inverted fluorescence micro-
scope for composite images of whole-tumor sections.
Hyperpolarization
For the hyperpolarization of pyruvate and glucose,
OXO63 trityl radical (Oxford Instruments, Abingdon,
UK) and DOTAREM (Guerbet, Roissy, France) were
added to either neat 13C1-pyruvic acid (Sigma Aldrich,
UK) or 3.3 to 3.45M 13Cu-glucose-d7 (Sigma Aldrich,
UK) in D2O, to final concentrations of 15mM (OXO63
trityl radical) and 1.5mM (DOTAREM) for both pyruvate
and glucose.
A total of 35.56 0.5mg (27mL) of the prepared pyr-
uvic acid sample was inserted into a HyperSense dDNP
system (Oxford Instruments) and polarized up to more
than 90% of maximum polarization (40–60min). The
hyperpolarized sample was dissolved with superheated
40 mM HEPES buffer solution and transferred to an auto-
mated injection system (19) in 4.5 s, for infusion into the
rat. For the pyruvate dissolution a predetermined aliquot
of 2.0M NaOH solution was added to the injection sys-
tem to neutralize the pyruvic acid acidity. The final
injectate concentration of pyruvate was approximately
80mM. Glucose was polarized to approximately 90% of
maximum polarization and transferred to the injection
system, as for pyruvate, with the exception of using deu-
terated water in the HEPES buffer solution. Quantities of
FIG. 2. Synthetic route for combretastatin CA1-P. * indicates the location of the 13CD3-labeled methyl group. Bn, benzyl; DIPEA, N,N-Dii-
sopropylethylamine; DMAP, 4-Dimethylaminopyridine; DMF, dimethylformamide; TBAF, tetra-n-butylammonium fluoride; TBS, tert-
butyldimethylsilyl; THF, tetrahydrofuran; TMSBr, Bromo(trimethyl)silane. (See Supporting Information for full details.)
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polarized glucose were varied for the desired final injec-
tate concentration (10–156mM).
The phosphorylated prodrug CA1-P, was synthesized
by adapting an existing synthetic procedure (20) to pro-
vide a 13C-labeled and deuterated methyl group (13CD3)
on the “B” ring of the molecule, as outlined in Figure 2.
The synthetic procedure and associated analytical data
are described in detail in the Supporting Information. A
total of 160mg 13CD3-CA1-P was dissolved in 175mL 1:1
DMSO:D2O, including 14mM Finland trityl radical
(Oxford Instruments) and polarized for approximately
3h before transfer to the injection system in deuterated
HEPES buffer solution, as for glucose.
MR Experiments
Each animal was placed in a supine position in a special-
ly developed animal holder and located at the iso-center
of a 7 Tesla MRI scanner (Bruker Biospec 70/30, Avance
III spectrometer, 120-mm diameter bore, 660 mT/m gradi-
ent strength insert, Bruker Biospin MRI GmbH, Ettlingen,
Germany). For evaluation of the intra-arterial injection
(IA) methodology, the hyperpolarized HEPES-buffered
pyruvate solution (80mM for most of the animals) was
administered directly to the tumor via the superior epigas-
tric artery cannula using a custom injection system (19).
Automated injection started immediately on receipt of the
hyperpolarized substrate by the injector (ie, 4.5 s after
opening of the solvent vessel valve on the HyperSense
polarizer). The injector was initially set to flow to waste
at 20mL/min to fill the cannula dead-space (0.8mL; Fig.
1). Then, 20mL at 10mL/min was delivered to the rat (to
overcome arterial blood pressure) followed by 180mL at
1mL/min to infuse the tumor with pyruvate. The total
injected pyruvate volume was therefore 200mL, resulting
in an approximate dose to the whole animal of 5mg/kg
body weight. The injection protocol was chosen, so that
the infused pyruvate was washed directly into the superi-
or epigastric artery supplying the tumor via femoral artery
blood flow. The estimated time from opening of the sol-
vent vessel valve on the polarizer to hyperpolarized pyru-
vate entering the rat’s vascular system was 7 to 8 s. The
13C-metabolite signals were localized by a 20 mm 13C/1H
surface coil (Bruker) above the tumor and 10 mm thick
slice selection (20 flip angle (FA); sweep width
(SW)¼ 50ppm; time domain points (TD)¼ 256; repetition
time (TR)¼1 s, number of excitations (NEX)¼ 1, number
of repetitions (NR)¼ 180). A 6.7-M 13C1-acetate phantom
was placed on top of the surface coil to provide a con-
stant reference signal for frequency setting and assessment
of reproducibility. To compare this method with the more
usual systemic intravenous (IV) injection, a control group
of rats bearing inguinal fat pad tumors was used, in
which a contralateral femoral vein was cannulated to
allow systemic IV infusion. In this case, the maximum
permissible volume of 5mL/kg body weight of the 80 mM
pyruvate solution was infused via the cannulated femoral
vein (equivalent to a pyruvate dose of 36mg/kg body
weight (ie, approximately 7 times higher than the whole
body dose used for IA administration). Intravenous infu-
sion was carried out with the same initial flow to waste
(0.8mL at 20mL/min to fill the cannula dead-space), fol-
lowed by a 5 mL/kg infusion over 13 s, using the automat-
ed injection system described previously. As for the IA
infusions, the estimated time from opening of the solvent
vessel valve on the polarizer to hyperpolarized pyruvate
entering the rat’s vascular system was 7 to 8 s. In a subset
of IA experiments, localization of the pyruvate/lactate sig-
nal was carried out using a spectral-spatial (spsp) selec-
tive pulse (21), combined with an echo planar read-out
trajectory, to rapidly image pyruvate to lactate conversion
in a single axial slice containing the tumor and
FIG. 3. (a) Tumor implantation site in the right inguinal cleft at different times after the start of IA infusion of methylene blue into a male
BDIX rat (see also Supporting Video S1). Note that the femoral artery remained clear of methylene blue during the infusion time. (b)
Fluorescent microbeads (green) trapped in the tumor vasculature stained for CD31 (red) following IA infusion. Nuclear staining (DAPI;
4’,6-diamidino-2-phenylindole) is shown in blue.
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surrounding tissue. The excitation frequencies were locat-
ed at the 13C1 resonant frequencies for pyruvate, lactate,
and acetate (field of view¼80  40mm, 32  32, slice
thickness¼ 12mm, TE/TR¼ 18.42/1000 ms, nominal
FA¼ 70o, NEX¼ 1, NR¼ 90).
To test the application of the method to a molecule
with a shorter T1,
13Cu-glucose-d7 (in vivo apparent T1
reported as 9 s (9)) was polarized and infused IA as
described previously at differing concentrations. The
hyperpolarized signal was acquired using the surface coil
described previously with a nonlocalized pulse-acquired
sequence (60ms block pulse, 20 FA, SW¼ 200ppm,
TD¼ 2048, TR¼ 1 s, NEX¼1, NR¼100). Hyperpolarized
13C-labeled CA1-P was administered IA using the injec-
tion protocol described previously and data acquired
using a nonlocalized spectroscopic acquisition with a
broadband radiofrequency (RF) pulse (60ms block pulse,
15 FA, SW¼ 200ppm, TD¼ 2048, NEX¼ 1, NR¼ 80).
Gadolinium Perfusion
Following IA infusion of hyperpolarized glucose, six of
the nine animals used were rapidly imaged while admin-
istering a gadolinium-based contrast agent via the tumor-
supplying artery, to investigate the perfusion of the
tissue-isolated tumors relative to surrounding normal tis-
sue in a larger cohort than used for optical imaging. The
same injection protocol as for the hyperpolarization
experiments was used. A 5:1 diluted solution of gado-
pentetate dimeglumine (Magnevist, Bayer Schering Phar-
ma AG, Berlin, Germany) was administered, and up to
100 FLASH images were acquired during and after the
infusion (field of view 40  40mm, 1  1mm slice, 64
 64, FA 30, TR/TE 50.05/6 ms, NEX¼ 1, NR¼ 100,
image acquired every 3.2 s).
Data Processing
All hyperpolarized spectra were processed from the raw
data using custom MATLAB software (MathWorks,
Natick, MA, USA), to Fourier transform, phase, and base-
line correct the spectra. Peaks of interest (eg, pyruvate/
lactate, glucose) were integrated over the time course to
produce 13C integral versus time curves. The forward
pyruvate-lactate conversion rate constant, kpl, was esti-
mated using a precursor-product relationship as previ-
ously described (22). Results are quoted as
mean6 standard error of mean (SEM), unless otherwise
stated. Where a linear regression line is fitted to the
data, the Pearson correlation coefficient, r, and statistical
significance, p, are quoted. The significance of differ-
ences between two groups was assessed in MATLAB
using the student’s two-tailed t-test, with equal variance
for unpaired data, with P<0.05 considered significant.
RESULTS
Perfusion of Tissue-Isolated Tumors
Preliminary optical imaging experiments using methy-
lene blue infusion via the cannulated saphenous artery
established that an IA infusion rate of 1mL/min effec-
tively perfused the tumor and overlying fat without any
observable perfusion of surrounding normal tissues or
retrograde flow along the femoral artery (Fig. 3a and
Supporting Video S1). Therefore, this flow rate was car-
ried forward to the MR experiments. Fluorescent
microbeads, infused at 1mL/min via the same route,
were distributed uniformly across tumor sections (Fig.
3b), indicating that the superior epigastric artery was the
critical source of blood flow to the whole tumor
microcirculation.
To support the optical imaging findings, a gadolinium-
based contrast agent was infused via the cannulated
saphenous artery, as described previously, following the
hyperpolarized glucose experiments. Single-slice 1H gradi-
ent echo images were acquired every 3.2 s before and dur-
ing gadolinium infusion. Figure 4 shows 1H FLASH
images of tumors just before a change in the 1H image
voxel intensity within the tumor region (denoted as “pre-
gadolinium”) and at the maximum decrease in 1H image
voxel intensity within the tumor region (denoted as “post-
gadolinium”), assumed to represent the maximum tumor
gadolinium concentration. Both time points were judged
by eye by two independent experts: S.R. and M.P. In
addition, the mean of all of the images acquired over 60 s
from the time of the pre-gadolinium image is shown for
each tumor (denoted as “mean-gadolinium”). The initial
change in image intensity was typically first observed at
approximately 9 s - similar to that observed for hyperpo-
larized pyruvate and glucose, as described subsequently.
Maximum gadolinium concentration occurred between 9
and 13 s after the first observed change. In some cases
during infusion, the entire tumor region became darker,
as a result of high gadolinium concentration substantially
shortening the T2, whereas the surrounding tissue was
unchanged. In other cases, changes in the tumor were
more heterogeneous; image intensity darkened or bright-
ened depending on the local gadolinium concentration.
This made quantitation of the perfusion changes problem-
atic. However, the mean-gadolinium images show that
there were substantial intensity changes in tumor but not
surrounding tissues over 60 s of Magnevist infusion, dur-
ing which time gadolinium uptake is mostly a reflection
of blood flow rate and vascular permeability (Fig. 4 and
Supporting video S2). This supports effective perfusion of
tumor tissue via the saphenous artery, confirming prelimi-
nary data from optical imaging (Fig. 3). Furthermore, the
data suggest that pre-infusion of glucose, at the concentra-
tions used, had little or no lasting influence on tumor vas-
cular function, consistent with previously published data
(23). At later time points than shown in Figure 4, voxel
intensity changes were observed in the surrounding tis-
sue, as the gadolinium was systemically distributed (see
Supporting Video S2).
Signal Enhancement by IA Administration: Pyruvate
Metabolism
Mean arterial blood pressure for cannulated rats immedi-
ately prior to IA infusion of pyruvate and slice-selected
scanning was 766 2 mmHg (n¼ 9) compared with 806 8
mmHg (n¼ 5) for the IV cannulated group. The equiva-
lent breathing rates were 5462 and 5767 breaths per
minute, respectively. These values were similar and not
significantly different between the two groups (P¼ 0.49
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FIG. 4. FLASH images acquired before and during IA infusion of one in five saline-diluted Magnevist (gadolinium-based contrast agent;
FA 30, TR/TE¼50.05/10.5 ms, 64  64, 40  40 mm). Magnevist was infused after completion of the hyperpolarized glucose experi-
ments in six of the nine animals shown in Figure 6b; glucose concentrations, top to bottom, are 10, 20, 20, 20, 42, and 63 mM. Each
row represents a single tumor. Images were acquired every 3.2 s, with the pre-gadolinium images in the left column showing the last
image acquired just before an observable change in image intensity (as judged by eye by S.R., M.P.) as a result of a high concentration
of gadolinium, typically approximately 6 s after commencing the injection protocol at time¼0. This time included 4.5 s allocated to
hyperpolarized sample transfer from the polarizer to the injection system. The post-gadolinium images in the middle column are the
images with the greatest change in image intensity within the tumor region (as judged by eye by S.R., M.P.) following the start of Mag-
nevist infusion. These images occurred 9 to 13 s after the initial change in voxel intensity and are assumed to represent the highest con-
centration of gadolinium obtained in the tumor tissue. The right column (mean-gadolinium) shows the mean of images acquired over 60
s, starting from the time point of the pre-gadolinium (left side) image. The full time course of images for the tumor in the sixth row is
shown in Supporting Video 2.
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and 0.51 for blood pressure and breathing rate, respec-
tively), indicating a similar physiological status.
The mean areas under the pyruvate and lactate signal
time course (AUC) were compared for the direct arterial
versus the systemic venous infusion routes (Fig. 5a). For
an 80-mM pyruvate infusion, the mean IA AUC was 4.6
and 1.6 times greater than the IV AUC for pyruvate and
lactate, respectively. The tumor weights for each group
were not significantly different (IA tumor¼ 1.4460.24 g
(n¼ 9) and IV tumor¼ 0.926 0.20 g (n¼5); P¼0.17). The
mean IA dose per kilogram of rat body weight was 5.46
0.5mg/kg (mean rat weight 2726 19 g; 1.4mg pyruvate
administered; n¼ 9), compared with a mean IV dose of
36mg/kg (mean rat weight 2976 8 g). Therefore, the actu-
al signal enhancement for the IA injected pyruvate was
33-fold (4.6*36/5). The IA pyruvate signal was first
observed above the noise level after 9.260.6 s, with a
signal maximum occurring at 15.76 1.1 s. This compares
to 10.660.7 s and 22.461.1 s for the IV times, respec-
tively. Correspondingly, the IA lactate signal was first
observed above the noise level at 11.66 0.8 s, with a sig-
nal maximum at 30.66 1.4 s. This compares to 14.66 0.5
s and 34.861.4 s for the IV times, respectively. A stu-
dent’s t-test showed a statistically significant shorter rise
time (time from first signal observation to signal maxi-
mum) for IA versus IV tumors for pyruvate (P¼ 0.007),
but not for lactate (P¼0.51).
Spectral-spatial pulse echo-planar imaging (EPI)
acquisitions in separate animals confirmed results for
methylene blue and gadolinium perfusion, showing that
most of the IA pyruvate initially perfused only the tumor
rather than the surrounding normal tissue, with a com-
plementary lactate signal in tumor tissue (Fig. 5b).
Applying a precursor-product model (22) to the slice
localized data, the rate constant for the conversion of
pyruvate to lactate, kpl, was 0.02060.004 s
-1 for IA injec-
tions (n¼9) compared with 0.05260.009 s-1 for IV injec-
tions (n¼ 5). These values were significantly different
(p¼ 0.022). Two further hyperpolarized pyruvate IA
injections were performed, in two separate male animals,
at lower doses. The estimated kpl for these were 0.035
and 0.023 s-1 for 10 and 20mM of injected pyruvate con-
centrations, respectively.
IA Administration of a Substrate with Short T1: Glucose
Metabolism
Hyperpolarized glucose was used as a readily available
test molecule that possesses a short T1, similar to the
proposed 13C-labeled CA1-P to optimize the acquisition
procedure. Following IA administration of hyperpolar-
ized glucose, the time-course signal could be first
detected at 8.160.5 s with a maximum signal at
15.66 0.4 s (Fig. 6a). Additionally, there was a strong
correlation (r¼ 0.93, p< 0.001) between glucose concen-
tration and glucose signal between 10 and 156mM (Fig.
6b). No lactate peak was observed. However, in a subset
of the in vivo experiments (3 of 9 shown in Fig. 6b), an
FIG. 5. (a) Hyperpolarized pyruvate and lactate tumor time courses for IA administration (red traces; n¼9: 7 male; 2 female) and IV
injection (blue traces; n¼5 male). Male rats weighed 2996 21 g for IA and 297618 g for IV (mean6SD); female rats weighed 174 and
181 g. Data were acquired every 1 s. Lines show mean values; error bars are SEM, shown at 10 s intervals for clarity. Integrals of signal
intensity are measured in arbitrary units (a.u.). Acetate integrals are offset from their true position by 1e6 for clarity. Time zero is the start
of sample dissolution, corresponding to the opening of the solvent vessel valve on the HyperSense polarizer. Based on known cannula
dead spaces and infusion rates, the approximate time for hyperpolarized pyruvate to enter the vascular system was 7 to 8 s from time
0 s, including 4.5 s to allow the sample to transit from the polarizer to the injection system, after which the injection protocol com-
menced. (b) Example of a composite spectral-spatial-EPI image. Top image shows the 1H structural image; middle and bottom images
show the13C pyruvate and lactate images superimposed on the 1H structural image, respectively. 13C images consist of data from 40
axial images acquired every 1 s and are normalized to the maximum intensity of the pyruvate signal.
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additional unknown peak was observed at 9 ppm up
field from the acetate phantom, at 174ppm, that was ten-
tatively assigned to glutamate. An example is shown in
Figure 6c. There was no relationship to glucose dose, as
two of the three tumors with the additional peak
received glucose at 20mM, and the third received
63mM. We also carried out further experiments using
the same single-slice spectral-spatial pulse as used for
EPI imaging of pyruvate (Fig. 5b), coupled with a one-
dimensional spectral acquisition. The spectral excitation
frequencies were set to those for glucose and lactate
(with a 50-ppm spectral acquisition window), in an
attempt to detect lactate production. However, no lactate
peak was observed (n¼ 5; data not shown).
IA Administration of a Hyperpolarized Drug:
Combretastatin
The signal from hyperpolarized 13C-labeled CA1-P was
too small to be observed in the individual time-course
data, but was clearly visible at 58ppm when all of the
time-course data were summed (Fig. 7a), matching a pre-
viously measured spectrum of CA1-P acquired for an
aqueous sample on a 9.4T spectrometer (Fig. 7b).
DISCUSSION
Direct infusion into a tumor-supplying artery enabled
rapid perfusion of the tumor tissue with hyperpolarized
substrate and a reduced systemic dose compared with
that from conventional IV injection. Optical and MR
imaging showed that IA administered substrates/contrast
agents almost exclusively perfused the tumor tissue on
initial injection.
The enhanced signal level obtained with this tech-
nique (more than 30-fold) allows for either reduced
administered dose or use of substrates with lower polari-
zation than the commonly used substrate, pyruvate.
Tumors used for IV infusion of pyruvate were approxi-
mately 36% smaller, by mass, than those used for IA
FIG. 6. (a) Hyperpolarized 13Cu-glucose-d7 time course for IA administration. Plot shows mean6SEM trace (n¼4) for 20 mM solution
(error bars are shown at 10-s intervals for clarity) and a single trace for 10-mM solution (all male). Integrals of signal intensity are mea-
sured in arbitrary units (a.u.). Data were acquired every 1 s. Time zero is the start of sample dissolution, corresponding to opening of
the solvent vessel valve on the HyperSense polarizer. (b) The AUC of hyperpolarized glucose time courses versus injected glucose con-
centration; the AUC is measured in arbitrary units (a.u.). Data include the examples shown in (a). Each point represents a single animal
(n¼9 male rats weighing 3066 27 g (mean6SD)). (c) Composite spectrum from 180 time points after injecting 63 mM hyperpolarized
13Cu-glucose-d7 in a single tumor. Peak at 173.9 ppm assigned to glutamate. Spectrum referenced to
13C1-glucose peak at 98 ppm. Art,
artifact.
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infusion. Although not a statistically significant differ-
ence, an increased signal intensity would have been
expected in the IV infused tumors had they been larger.
However, this clearly cannot account for the more than
30-fold pyruvate signal enhancement obtained for IA
administration. As expected, the rise time for pyruvate
was significantly shorter for IA administration than IV
administration, indicating faster delivery to the tumor.
However, the lactate rise time was unaffected by the
route of administration, suggesting that the increased
pyruvate delivery had little effect on its metabolism.
The significantly enhanced pyruvate signal in the
tumor for IA compared with IV administration indicates
rapid extraction of pyruvate from the circulation into the
tumor tissue on first pass. The circulation time in rats at
the body weights used in our experiments was approxi-
mately 7 s (24), so the recirculation of hyperpolarized
pyruvate would have approximately coincided with the
end of the infusion period. In addition, any pyruvate not
extracted by the tumor tissue on first pass would have
been largely diluted in the systemic circulation, while
also rapidly losing signal. Taken together, these consid-
erations suggest that recirculation of pyruvate had little
influence on the observed pyruvate kinetics in the
tumor.
An injected concentration of 80 mM pyruvate, used for
most animals in this study, is within the range typically
used for IV administration of pyruvate in hyperpolariza-
tion experiments. In our IV case, this equated to 36mg/
kg or 0.4 mmol/kg total dose. Janich et al (25) reported
partial tissue saturation in rat liver, kidney, and heart by
pyruvate at 0.2 to 0.4 mmol/kg pyruvate. Our estimated
kpl values decreased with an increasing IA dose (between
10 and 80mM in 200mL) and were lower than the kpl
estimated from IV administration of pyruvate, suggesting
saturation of tumor lactate dehydrogenase, at least in the
IA case. This would be expected based on the large total
doses delivered directly to the tumor, and would explain
why the observed increase in the pyruvate signal for IA
versus IV infusion was not matched by a corresponding
increase in the lactate signal (Fig. 5). However, because
kpl represents the fractional turnover of pyruvate, rather
than the absolute rate of pyruvate to lactate production,
it is difficult to draw any firm conclusions regarding
enzyme kinetics in the face of different concentrations of
administered pyruvate. Furthermore, the relative ampli-
tude of the lactate time-course signal also depends on
the size of the endogenous lactate pool, as there is a lim-
it imposed on the observable 13C lactate signal due to
the lactate pool’s ability to retain 13C spins (26). Howev-
er, the current model provides a means of accurately
titrating administered doses in a more controlled manner
than for systemic administration, either to avoid or spe-
cifically investigate processes such as tissue saturation
and toxicity. In addition, accurate knowledge of the con-
centration of administered substances in the tumor arte-
rial blood supply provides the opportunity for accurate
estimation of blood-tissue exchange of substrates and a
ready arterial input function for modeling purposes, at
least for the first few seconds of infusion.
The concentrations of IA administered glucose used
in our study were at the upper range of physiological
FIG. 7. (a): Hyperpolarized in vivo tumor
signal from CA1-P (chemical structure
shown) following IA infusion in a single
233 g male rat (FA¼25, TR¼1 s,
SW¼200 ppm, TD¼512, NEX¼80); 13C
labeled at the 15 position. (b) 13C{1H}-
inverse gated spectrum of 15 mM CA1-P
dissolved in H2O (20% D2O) with 80 mM
13C1,2-acetate as reference peaks. Inset
shows expanded part of the spectrum
containing CA1-P signal. Spectrum
acquired on a 9.4 T Bruker Avance III
spectrometer (FA¼90, TR¼100 s,
SW¼200 ppm, TD¼8062, NEX¼512).
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blood glucose concentrations. Observation of glucose
metabolism was limited to a small subset of tumors,
despite trialing different MR acquisitions methods (eg,
slice selection, spsp RF excitation) for improved signal
detection. Although a tentative assignment, the observa-
tion of glucose to glutamate conversion, but not lactate,
is surprising given that tumors are generally character-
ized by lactate production under aerobic as well as
anaerobic conditions. However, high glucose exposure
has been found to increase cellular glutamate (via a-keto-
glutarate) in a number of different cell types in vitro
(27). Further investigations would be needed to positive-
ly assign the peak that we identified in a subset of the
glucose experiments to glutamate.
The additional metabolic steps from glucose to lactate
production or reduced active transport of glucose into
cells compared with pyruvate, coupled with a short T1
for glucose, may explain the lack of a tumor lactate sig-
nal, in contrast to the readily observable lactate signal on
administration of hyperpolarized pyruvate. However,
Rodrigues et al reported glucose-to-lactate conversion in
the mouse T cell lymphoma (EL4) and Lewis lung carci-
noma following systemic IV administration of hyperpo-
larized glucose (9). It is possible that glucose metabolism
is highly dependent on the tumor model used. Rodrigues
et al reported a steady-state lactate concentration of
20.76 3.0mmol/g for the EL4 tumor, whereas we previ-
ously reported a concentration of 3.060.2 mmol/g for the
P22 tumor (28). This lower concentration is consistent
with the P22 tumor being relatively well perfused and
oxygenated (29,30). A smaller lactate pool in the P22
tumor could also contribute to the lack of observable lac-
tate signal on administration of hyperpolarized glucose.
It is possible that further improvements in polarization
level or experimental sensitivity could enable improved
MR detection of glucose metabolism.
Despite the desirability of imaging drug metabolism
directly, only a drug’s indirect effect on metabolism has
previously been shown using hyperpolarized MRS (31).
Hyperpolarized drug detection is hampered by short T1
relaxation times that are on the order 1 to 10 s (6). Typi-
cal drug molecules possess molecular weights of a few
hundred Daltons that can result in molecular rotational
correlation times that are ideally suited to provide an
efficient relaxation pathway. By a judicious labeling
strategy (ie, deuteration and 13C label location), T1 relax-
ation time can be lengthened to the point where it is fea-
sible to administer hyperpolarized drugs without too
much signal loss. Relatively large amounts of CA1-P
were needed in the current study to observe an in vivo
signal, and further work is clearly required to improve
the polarization of these molecules. The pharmacokinet-
ics of CA1-P and its close analogues suggest that its
metabolism is rapid (32). However, its metabolic conver-
sion may still be slow compared with hyperpolarized
signal lifetime. Therefore, the lack of any observable
daughter metabolite in the MR spectrum could be the
result of a combination of relatively slow metabolism
and low level of hyperpolarization. A limitation on the
use of hyperpolarization for studying drug metabolism is
undoubtedly its restricted use to drugs with rapid metab-
olism, compatible with the lifetime of the hyperpolarized
signal. However, our method shows that it is possible to
observe hyperpolarized drugs in vivo without the
requirement to administer a large systemic dose. The
method has the potential to directly monitor drug distri-
bution and metabolism kinetics in tumors, with the pos-
sibility of observing unforeseen side reactions.
CONCLUSIONS
Here we report a method that enables expansion of the
range of observable hyperpolarization targets for tumor
studies to include those with lower levels of polarized
signal, shorter T1 relaxation times, and those whose sys-
temic toxicity is prohibitive if administered intravenous-
ly. Although we envisage the main utility of IA
administration to be for preclinical studies of tumor
energy and drug metabolism, its use in humans is theo-
retically possible in situations in which the IA route can
be used for chemotherapy, such as during treatment of
colorectal cancer liver metastases. Hitherto, hyperpolar-
ized MRS/MRI has been used to observe indirectly the
effect of drug treatment on tumor metabolism. For the
first time there is the possibility of directly observing a
drug molecule in vivo by 13C MRS.
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SUPPORTING INFORMATION
Additional Supporting Information may be found in the online version of
this article
Video S1. Tumor implantation site during perfusion with methylene blue.
Video S2. FLASH images acquired every 3.2 s (30 FA, TR/TE 50.05/10.5
ms, 64 3 64, 40 3 40 mm during of Injection of 1 in 5 saline-diluted gado-
linium (Magnevist) using the same injection protocol as for hyperpolarized
experiments. The video is for the same animals as for the sixth row images
in Figure 4.
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